Beyond 48 to 60 hours, life-threatening toxicities and even death may not be preventable. Early and rapid reduction of methotrexate (MTX) concentrations can lower the risk of irreversible damage.1
Consensus guidelines for use recommend administration of Voraxaze® at 48 hours following initiation of high-dose methotrexate (HDMTX) therapy when MTX concentrations are above 5 μM (2.27 μg/mL) and the serum creatinine is elevated relative to the baseline measurement.1
Over the past 25 years, the National Comprehensive Cancer Network (NCCN) has developed guidelines in oncology to document evidence-based, consensus-driven management to ensure that all patients receive treatment that is most likely to lead to optimal outcomes.
Voraxaze® is included in the following guidelines: